ProQR Therapeutics (NASDAQ:PRQR – Get Rating) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.81 and traded as high as $0.85. ProQR Therapeutics shares last traded at $0.84, with a volume of 436,743 shares.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, May 9th. Chardan Capital cut shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, August 12th. Cantor Fitzgerald cut shares of ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, August 15th. Raymond James upgraded shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target on the stock in a report on Friday, August 12th. Finally, HC Wainwright cut their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a report on Monday, May 9th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $5.00.
Get ProQR Therapeutics alerts:ProQR Therapeutics Stock Up 2.3 %
The company has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.98. The company has a market cap of $59.61 million, a P/E ratio of -0.84 and a beta of 0.80. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The business had revenue of $1.09 million for the quarter, compared to the consensus estimate of $1.21 million. ProQR Therapeutics had a negative return on equity of 57.34% and a negative net margin of 1,859.05%. On average, equities analysts anticipate that ProQR Therapeutics will post -0.81 EPS for the current year.Institutional Trading of ProQR Therapeutics
Several institutional investors have recently bought and sold shares of PRQR. ProShare Advisors LLC purchased a new position in ProQR Therapeutics during the fourth quarter worth approximately $80,000. Coastal Bridge Advisors LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $85,000. Corton Capital Inc. acquired a new position in ProQR Therapeutics during the 4th quarter worth $280,000. Virtu Financial LLC acquired a new position in ProQR Therapeutics during the 2nd quarter worth $48,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ProQR Therapeutics by 82.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,973 shares of the biopharmaceutical company's stock worth $560,000 after acquiring an additional 31,614 shares in the last quarter.
About ProQR Therapeutics
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Featured Articles
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- PENN Entertainment Stock is Reset and Ready to Rebound
- 3 Payroll Software Makers Set For Growth In 2023
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.